Latest news with #BioArctic
Yahoo
6 days ago
- Business
- Yahoo
BioArctic's Capital Markets Day 2025 - entering a new era of growth
STOCKHOLM, June 2, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event, which starts at 10:30 CET, will be broadcast live online. Over the past 20 years, BioArctic has built a thriving company based on a foundation of solid science and innovation, strong finances and an organization with well-educated staff and a value-driven corporate culture. At the Capital Markets Day, management will outline BioArctic's ambitions for 2030 which focuses on building Sweden's next major pharmaceutical company. This will be achieved by: building a balanced and broad pipeline with projects in all stages of development, adding additional successful global partnerships, and establishing Leqembi® as a treatment for Alzheimer's disease in the Nordics ensuring finances that allow for both investing in growth while giving recurring dividends to shareholders. To achieve this, the company will accelerate innovation into a broader area of severe brain diseases, proactively work with business development to maximize the value of each project, and work to ensure a successful launch of Leqembi in the Nordic region. The presentation for the Capital Markets Day can be found on A recording of the Capital Markets Day will be available later today on BioArctic's website. AGENDA 10:30 BioArctic today and tomorrow Precision neurology and severe brain disease experiencing unprecedented opportunities for innovation. Chief Executive Officer Gunilla Osswald will discuss how BioArctic is positioning itself to capture these global possibilities and outline the company's ambitions toward 2030. 11:00 FinancialsFollowing the recent license agreement with Bristol Myers Squibb and with continuous royalties from Leqembi sales, BioArctic expects to achieve profitability from this year onwards. Anders Martin-Löf, Chief Financial Officer, will outline what this strengthened financial position means for shareholders and BioArctic's future opportunities. 11:20 R&D StrategyBased on the same principle as Leqembi, BioArctic has built a project portfolio with selective antibodies targeting aggregated forms of misfolded proteins in the brain. Chief R&D Officer Johanna Fälting will outline the overarching research strategy and explain how BioArctic's integrated antibody and BrainTransporter™ platforms create opportunities across several disease areas. 11:50 Q&A 12:10 Lunch 13:00 LeqembiLeqembi is the first fully approved disease-modifying treatment for early Alzheimer's disease, marking a transformational shift in the treatment landscape. Anna-Kaija Grönblad, Chief Commercial Officer, will discuss this evolving paradigm, provide insights into global and European market developments, and outline BioArctic's preparations for the Nordic launch. 13:20 Key opinion leader: Disease modifying treatment for Alzheimer's disease in clinical useSince the initial approval of Leqembi in the United States in January 2023, clinicians have gained important real-world experience with this groundbreaking therapy for early Alzheimer's disease. Professor Lawrence S. Honig from Columbia University's Department of Neurology will present clinical insights from US practice and discuss the practical challenges and opportunities of implementing this new treatment paradigm. 14:00 Q&A 14:15 BrainTransporter-technologyBiological drugs hold enormous potential for treating brain diseases, but the blood-brain barrier has historically prevented their effective delivery. Chief Scientific Officer Per-Ola Freskgård will present how BioArctic's breakthrough BrainTransporter technology can deliver antibodies with up to 70 times greater brain exposure and superior distribution and discuss the commercial opportunities this proprietary platform creates. 14:55 ExidavnemabBioArctic's antibody exidavnemab targets alpha-synuclein, a key protein involved in multiple neurodegenerative conditions. Gabrielle Åhlberg Hillert, Chief Medical Officer, will provide an update on the Phase 2 program, explain how exidavnemab differentiates from other late-stage antibodies, and discuss how it could address significant unmet medical needs in alpha-synuclein diseases such as Parkinson's disease, Multiple System Atrophy, and Lewy body dementia. 15.15 Q&A 15.30 Concluding remarks Short summary by Gunilla Osswald, Chief Executive Officer The information was released for public disclosure, through the agency of the contact persons below, on June 2, 2025, at 10:30 CET. For further information, please contact: Oskar Bosson, VP Communications and Investor RelationsE-mail: +46 70 410 71 80 Charlotte af Klercker, Senior Director Sustainability and CommunicationsE-mail: Telephone: +46 73 515 09 70 About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit This information was brought to you by Cision The following files are available for download: BioArctic’s Capital Markets Day 2025 â€" entering a new era of growth View original content: SOURCE BioArctic
Yahoo
6 days ago
- Business
- Yahoo
BioArctic's Capital Markets Day 2025 - entering a new era of growth
STOCKHOLM, June 2, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event, which starts at 10:30 CET, will be broadcast live online. Over the past 20 years, BioArctic has built a thriving company based on a foundation of solid science and innovation, strong finances and an organization with well-educated staff and a value-driven corporate culture. At the Capital Markets Day, management will outline BioArctic's ambitions for 2030 which focuses on building Sweden's next major pharmaceutical company. This will be achieved by: building a balanced and broad pipeline with projects in all stages of development, adding additional successful global partnerships, and establishing Leqembi® as a treatment for Alzheimer's disease in the Nordics ensuring finances that allow for both investing in growth while giving recurring dividends to shareholders. To achieve this, the company will accelerate innovation into a broader area of severe brain diseases, proactively work with business development to maximize the value of each project, and work to ensure a successful launch of Leqembi in the Nordic region. The presentation for the Capital Markets Day can be found on A recording of the Capital Markets Day will be available later today on BioArctic's website. AGENDA 10:30 BioArctic today and tomorrow Precision neurology and severe brain disease experiencing unprecedented opportunities for innovation. Chief Executive Officer Gunilla Osswald will discuss how BioArctic is positioning itself to capture these global possibilities and outline the company's ambitions toward 2030. 11:00 FinancialsFollowing the recent license agreement with Bristol Myers Squibb and with continuous royalties from Leqembi sales, BioArctic expects to achieve profitability from this year onwards. Anders Martin-Löf, Chief Financial Officer, will outline what this strengthened financial position means for shareholders and BioArctic's future opportunities. 11:20 R&D StrategyBased on the same principle as Leqembi, BioArctic has built a project portfolio with selective antibodies targeting aggregated forms of misfolded proteins in the brain. Chief R&D Officer Johanna Fälting will outline the overarching research strategy and explain how BioArctic's integrated antibody and BrainTransporter™ platforms create opportunities across several disease areas. 11:50 Q&A 12:10 Lunch 13:00 LeqembiLeqembi is the first fully approved disease-modifying treatment for early Alzheimer's disease, marking a transformational shift in the treatment landscape. Anna-Kaija Grönblad, Chief Commercial Officer, will discuss this evolving paradigm, provide insights into global and European market developments, and outline BioArctic's preparations for the Nordic launch. 13:20 Key opinion leader: Disease modifying treatment for Alzheimer's disease in clinical useSince the initial approval of Leqembi in the United States in January 2023, clinicians have gained important real-world experience with this groundbreaking therapy for early Alzheimer's disease. Professor Lawrence S. Honig from Columbia University's Department of Neurology will present clinical insights from US practice and discuss the practical challenges and opportunities of implementing this new treatment paradigm. 14:00 Q&A 14:15 BrainTransporter-technologyBiological drugs hold enormous potential for treating brain diseases, but the blood-brain barrier has historically prevented their effective delivery. Chief Scientific Officer Per-Ola Freskgård will present how BioArctic's breakthrough BrainTransporter technology can deliver antibodies with up to 70 times greater brain exposure and superior distribution and discuss the commercial opportunities this proprietary platform creates. 14:55 ExidavnemabBioArctic's antibody exidavnemab targets alpha-synuclein, a key protein involved in multiple neurodegenerative conditions. Gabrielle Åhlberg Hillert, Chief Medical Officer, will provide an update on the Phase 2 program, explain how exidavnemab differentiates from other late-stage antibodies, and discuss how it could address significant unmet medical needs in alpha-synuclein diseases such as Parkinson's disease, Multiple System Atrophy, and Lewy body dementia. 15.15 Q&A 15.30 Concluding remarks Short summary by Gunilla Osswald, Chief Executive Officer The information was released for public disclosure, through the agency of the contact persons below, on June 2, 2025, at 10:30 CET. For further information, please contact: Oskar Bosson, VP Communications and Investor RelationsE-mail: +46 70 410 71 80 Charlotte af Klercker, Senior Director Sustainability and CommunicationsE-mail: Telephone: +46 73 515 09 70 About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit This information was brought to you by Cision The following files are available for download: BioArctic’s Capital Markets Day 2025 â€" entering a new era of growth View original content: SOURCE BioArctic Sign in to access your portfolio
Yahoo
25-02-2025
- Business
- Yahoo
High Insider Owned Growth Stocks With Earnings Up To 69%
In the midst of geopolitical tensions and shifting consumer spending patterns, global markets have experienced a volatile week, with major U.S. indexes seeing early gains erased by sharp losses later on. As investors navigate these uncertainties, growth companies with high insider ownership can be particularly appealing due to their potential alignment of interests between company insiders and shareholders, which may provide an added layer of confidence in turbulent times. Name Insider Ownership Earnings Growth Archean Chemical Industries (NSEI:ACI) 22.9% 50.1% Seojin SystemLtd (KOSDAQ:A178320) 32.1% 39.9% Clinuvel Pharmaceuticals (ASX:CUV) 10.4% 26.2% SKS Technologies Group (ASX:SKS) 29.7% 24.8% Pricol (NSEI:PRICOLLTD) 25.4% 25.2% Laopu Gold (SEHK:6181) 36.4% 43.2% Plenti Group (ASX:PLT) 12.7% 120.1% HANA Micron (KOSDAQ:A067310) 18.3% 119.4% Fulin Precision (SZSE:300432) 13.6% 71% Findi (ASX:FND) 35.8% 133.7% Click here to see the full list of 1450 stocks from our Fast Growing Companies With High Insider Ownership screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★★★ Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK21.66 billion. Operations: BioArctic generates its revenue primarily from the biotechnology segment, totaling SEK257.35 million. Insider Ownership: 33.8% Earnings Growth Forecast: 38.5% p.a. BioArctic's recent collaboration with Bristol Myers Squibb, involving a US$100 million upfront payment and potential milestones up to US$1.25 billion, highlights its growth potential. Despite volatile share prices, BioArctic is expected to achieve high revenue growth of 32.1% annually, surpassing market averages. The company is forecasted to become profitable within three years with a strong return on equity projected at 37.5%. While insider transactions have not been substantial recently, the stock trades significantly below estimated fair value. Navigate through the intricacies of BioArctic with our comprehensive analyst estimates report here. The valuation report we've compiled suggests that BioArctic's current price could be quite moderate. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Angelalign Technology Inc. is an investment holding company that focuses on researching, developing, designing, manufacturing, and marketing clear aligner treatment solutions in the People's Republic of China with a market cap of approximately HK$10.84 billion. Operations: The company generates revenue primarily from its Dental Equipment & Supplies segment, totaling CN¥1.72 billion. Insider Ownership: 17.6% Earnings Growth Forecast: 69.6% p.a. Angelalign Technology is poised for significant earnings growth, forecasted at 69.6% annually, outpacing the Hong Kong market. Despite a current profit margin decline to 2.5%, the company trades at 13.2% below its estimated fair value with analysts predicting a stock price increase of 28%. Revenue growth is projected at 14.5% per year, exceeding market averages but not reaching high-growth benchmarks. Recent address changes indicate ongoing operational adjustments without impacting insider trading activities. Dive into the specifics of Angelalign Technology here with our thorough growth forecast report. In light of our recent valuation report, it seems possible that Angelalign Technology is trading beyond its estimated value. Simply Wall St Growth Rating: ★★★★★★ Overview: APT Medical Inc. focuses on the research, development, manufacturing, and supply of electrophysiology and vascular interventional medical devices in China, with a market cap of CN¥36.74 billion. Operations: The company generates its revenue primarily from medical products, amounting to CN¥1.96 billion. Insider Ownership: 22.1% Earnings Growth Forecast: 28.8% p.a. APT Medical's recent earnings report shows strong growth, with sales reaching CNY 2.07 billion and net income increasing to CNY 673.48 million. Earnings per share rose to CNY 6.96, reflecting robust financial health. The company's revenue is forecasted to grow at a substantial rate of 29.1% annually, outpacing the Chinese market average of 13.4%. Despite no significant insider trading activity recently, high insider ownership aligns interests with shareholders and supports its growth trajectory. Unlock comprehensive insights into our analysis of APT Medical stock in this growth report. Our comprehensive valuation report raises the possibility that APT Medical is priced higher than what may be justified by its financials. Take a closer look at our Fast Growing Companies With High Insider Ownership list of 1450 companies by clicking here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include OM:BIOA B SEHK:6699 and SHSE:688617. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
27-01-2025
- Business
- Yahoo
Tikehau Capital And 2 More Stocks That May Be Priced Below Their Estimated Worth
As global markets navigate a landscape marked by political developments and economic shifts, U.S. stocks have surged to record highs, fueled by optimism over trade policies and advancements in artificial intelligence. Amidst this buoyant market environment, identifying stocks that may be undervalued can offer potential opportunities for investors seeking to capitalize on discrepancies between market price and intrinsic value. Name Current Price Fair Value (Est) Discount (Est) Alltop Technology (TPEX:3526) NT$264.50 NT$526.72 49.8% Berkshire Hills Bancorp (NYSE:BHLB) US$28.32 US$56.60 50% Shenzhen Yinghe Technology (SZSE:300457) CN¥18.80 CN¥37.54 49.9% World Fitness Services (TWSE:2762) NT$92.70 NT$184.63 49.8% Vertiseit (OM:VERT B) SEK50.20 SEK99.93 49.8% Fudo Tetra (TSE:1813) ¥2153.00 ¥4301.30 49.9% Greenworks (Jiangsu) (SZSE:301260) CN¥13.95 CN¥27.81 49.8% Shinko Electric Industries (TSE:6967) ¥5854.00 ¥11678.68 49.9% Jiangsu Chuanzhiboke Education Technology (SZSE:003032) CN¥9.10 CN¥18.19 50% Tenable Holdings (NasdaqGS:TENB) US$43.39 US$86.65 49.9% Click here to see the full list of 887 stocks from our Undervalued Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Overview: Tikehau Capital is an alternative asset management group with €46.1 billion in assets under management and a market capitalization of approximately €3.72 billion. Operations: The company's revenue segments include €173.11 million from investment activities and €322.94 million from asset management activities. Estimated Discount To Fair Value: 42.4% Tikehau Capital is trading at €21.65, significantly below its estimated fair value of €37.59, highlighting potential undervaluation based on cash flows. Despite a dividend yield of 3.46% not being well covered by free cash flows, the company shows strong growth prospects with earnings expected to rise by 35.9% annually, outpacing the French market's forecasted growth rate of 12%. However, debt coverage by operating cash flow remains a concern for investors. The analysis detailed in our Tikehau Capital growth report hints at robust future financial performance. Click to explore a detailed breakdown of our findings in Tikehau Capital's balance sheet health report. Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK19.23 billion. Operations: The company's revenue primarily comes from its biotechnology segment, amounting to SEK167.14 million. Estimated Discount To Fair Value: 37.5% BioArctic is trading at SEK 217.6, significantly below its estimated fair value of SEK 348.11, suggesting potential undervaluation based on cash flows. The company recently secured a US$100 million upfront payment and up to US$1.25 billion in milestone payments from a licensing agreement with Bristol Myers Squibb, enhancing its cash flow prospects. Despite recent losses, BioArctic's revenue is forecasted to grow at 41.4% annually, surpassing market expectations and supporting future profitability projections within three years. The growth report we've compiled suggests that BioArctic's future prospects could be on the up. Get an in-depth perspective on BioArctic's balance sheet by reading our health report here. Overview: Ypsomed Holding AG, with a market cap of CHF4.87 billion, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. Operations: Ypsomed Holding generates revenue primarily from two segments: Ypsomed Diabetes Care, contributing CHF176.61 million, and Ypsomed Delivery Systems, accounting for CHF428.94 million. Estimated Discount To Fair Value: 30.7% Ypsomed Holding, trading at CHF 357, appears undervalued relative to its estimated fair value of CHF 515.29. Despite recent earnings challenges with net income dropping to CHF 0.0326 million for the half year ending September 2024, the company's earnings are forecasted to grow significantly at over 40% annually. This growth trajectory surpasses Swiss market expectations and is supported by innovative product approvals like the mylife YpsoPump in Canada, enhancing future revenue potential despite high debt levels. Insights from our recent growth report point to a promising forecast for Ypsomed Holding's business outlook. Click here to discover the nuances of Ypsomed Holding with our detailed financial health report. Click this link to deep-dive into the 887 companies within our Undervalued Stocks Based On Cash Flows screener. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:TKO OM:BIOA B and SWX:YPSN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
27-01-2025
- Business
- Yahoo
3 Growth Companies Insiders Own With Earnings Growth Up To 51%
As global markets continue to react to political developments and economic indicators, U.S. stocks have been marching toward record highs, buoyed by optimism around softer tariffs and artificial intelligence investments. In this environment of cautious optimism, growth companies with high insider ownership can offer intriguing opportunities for investors, as they often signal confidence in the company's future prospects and alignment between management and shareholders' interests. Name Insider Ownership Earnings Growth Kirloskar Pneumatic (BSE:505283) 30.3% 26.3% Archean Chemical Industries (NSEI:ACI) 22.9% 41.2% Clinuvel Pharmaceuticals (ASX:CUV) 10.4% 26.2% Propel Holdings (TSX:PRL) 36.8% 38.9% Pharma Mar (BME:PHM) 11.9% 55.1% Brightstar Resources (ASX:BTR) 16.2% 84.1% Fine M-TecLTD (KOSDAQ:A441270) 17.2% 135% Fulin Precision (SZSE:300432) 13.6% 71% HANA Micron (KOSDAQ:A067310) 18.3% 119.4% Findi (ASX:FND) 35.8% 110.7% Click here to see the full list of 1465 stocks from our Fast Growing Companies With High Insider Ownership screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★★★ Overview: BioArctic AB (publ) is a Swedish company that develops biological drugs for central nervous system disorders, with a market cap of SEK19.23 billion. Operations: The company's revenue is derived from its biotechnology segment, amounting to SEK167.14 million. Insider Ownership: 33.9% Earnings Growth Forecast: 51.3% p.a. BioArctic is poised for significant growth, with revenue expected to increase by 41.4% annually, outpacing the market. Despite a volatile share price and no substantial insider buying recently, it trades at 37.5% below fair value estimates. The company has secured a lucrative agreement with Bristol Myers Squibb for its PyroGlu-Ab antibody program, potentially earning up to US$1.25 billion in milestone payments alongside royalties, which could enhance profitability and support future growth initiatives. Get an in-depth perspective on BioArctic's performance by reading our analyst estimates report here. Our valuation report unveils the possibility BioArctic's shares may be trading at a discount. Simply Wall St Growth Rating: ★★★★☆☆ Overview: HMS Networks AB (publ) provides products that facilitate communication and information sharing for industrial equipment globally, with a market cap of SEK23.06 billion. Operations: Revenue Segments (in millions of SEK): Wireless Communications Equipment: 3012.72 Insider Ownership: 12.6% Earnings Growth Forecast: 41% p.a. HMS Networks is set for robust growth, with earnings projected to rise 41% annually, surpassing the Swedish market. Revenue growth at 17.6% per year is also strong but below the high-growth threshold. Despite a recent decline in profit margins from 20.2% to 11.5%, insider activity shows more buying than selling recently, though not in large volumes. The stock trades slightly below fair value but carries a high level of debt that warrants attention. Dive into the specifics of HMS Networks here with our thorough growth forecast report. According our valuation report, there's an indication that HMS Networks' share price might be on the expensive side. Simply Wall St Growth Rating: ★★★★★★ Overview: APT Medical Inc. focuses on the research, development, manufacturing, and supply of electrophysiology and vascular interventional medical devices in China with a market cap of CN¥35.92 billion. Operations: The company's revenue is primarily derived from its medical products segment, totaling CN¥1.96 billion. Insider Ownership: 22% Earnings Growth Forecast: 28.8% p.a. APT Medical is poised for substantial growth, with earnings expected to rise significantly, outpacing the Chinese market. Revenue is forecasted to grow at 29.1% annually, well above the market average of 13.4%. Despite no recent insider trading activity, the company's high-quality earnings and anticipated return on equity of 29.7% in three years highlight its strong financial health. Recent events include an upcoming shareholders meeting in January 2025 and a Q3 earnings call last November. Delve into the full analysis future growth report here for a deeper understanding of APT Medical. Insights from our recent valuation report point to the potential overvaluation of APT Medical shares in the market. Click through to start exploring the rest of the 1462 Fast Growing Companies With High Insider Ownership now. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include OM:BIOA B OM:HMS and SHSE:688617. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
